Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ADC Therapeutics (ADCT) Treasury Shares (2019 - 2026)

ADC Therapeutics has reported Treasury Shares over the past 8 years, most recently at $205000.0 for Q1 2026.

  • Quarterly results put Treasury Shares at $205000.0 for Q1 2026, down 0.97% from a year ago — trailing twelve months through Mar 2026 was $205000.0 (down 0.97% YoY), and the annual figure for FY2025 was $205000.0, down 6.82%.
  • Treasury Shares reached $9.1 million in Q1 2026 per ADCT's latest filing, up from $4.6 million in the prior quarter.
  • Across five years, Treasury Shares topped out at $9.1 million in Q1 2026 and bottomed at $2.6 million in Q3 2025.
  • Median Treasury Shares over the past 5 years was $5.4 million (2024), compared with a mean of $5.2 million.
  • The largest annual shift saw Treasury Shares plummeted 2875.0% in 2022 before it skyrocketed 177.83% in 2024.
  • Over 5 years, Treasury Shares stood at -$697503.0 in 2022, then surged by 177.56% to $541000.0 in 2023, then plummeted by 59.33% to $220000.0 in 2024, then fell by 6.82% to $205000.0 in 2025, then changed by 0.0% to $205000.0 in 2026.
  • Business Quant data shows Treasury Shares for ADCT at $205000.0 in Q1 2026, $205000.0 in Q4 2025, and $205000.0 in Q3 2025.